Aptamers in immunological research

Immunology Letters

Volumn 162, Issue 2, 2014, Pages 252-255

  Nezlin, Roald ^a  

^a WEIZMANN INSTITUTE OF SCIENCE   (Israel)

Author keywords

Aptamers; Aptamers in immunoassays; Complexes of aptamers with immunoglobulins; Modulation of immune reactions; Reactions of aptamers with cell receptors; Tumor immunology

Indexed keywords

APTAMER; CELL RECEPTOR; CHEMOKINE RECEPTOR CXCR4; COMPLEMENT COMPONENT C5; FC RECEPTOR; IMMUNOGLOBULIN; IMMUNOGLOBULIN E; IMMUNOGLOBULIN G1; INTERLEUKIN 10; INTERLEUKIN 10 RECEPTOR ANTIBODY; MEMBRANE PROTEIN; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY CD137; MONOCLONAL ANTIBODY CD28; SECONDARY LYMPHOID TISSUE CHEMOKINE; UNCLASSIFIED DRUG; IMMUNOGLOBULIN FC FRAGMENT;

ADAPTIVE IMMUNITY; ANTIGEN BINDING; ANTINEOPLASTIC ACTIVITY; BINDING AFFINITY; BINDING SITE; CANCER IMMUNOTHERAPY; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CYTOKINE PRODUCTION; HUMAN; IMMUNE RESPONSE; IMMUNOASSAY; IMMUNOMODULATION; IMMUNOSTIMULATION; INNATE IMMUNITY; LIGAND BINDING; LYMPHOCYTE PROLIFERATION; LYMPHOMA; NONHUMAN; PROTEIN PROTEIN INTERACTION; PROTEIN STRUCTURE; RECEPTOR BLOCKING; REVIEW; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; TUMOR IMMUNITY; ANIMAL; AUTOIMMUNE DISEASES; CHEMISTRY; IMMUNOLOGY; NEOPLASMS; PATHOLOGY; PROCEDURES;

ANIMALS; APTAMERS, NUCLEOTIDE; AUTOIMMUNE DISEASES; HUMANS; IMMUNOASSAY; IMMUNOGLOBULIN FC FRAGMENTS; NEOPLASMS; T-LYMPHOCYTES;

EID: 84912074641     PISSN: 01652478     EISSN: 18790542     Source Type: Journal    
DOI: 10.1016/j.imlet.2014.10.001     Document Type: Review

References (43)

1. Patel D.J. Structural analysis of nucleic acid aptamers. Curr Opin Chem Biol 1997, 1:32-46.
2. Tuerk C., Gold L. Systematic evolution of ligands by exponential enrichment: RNA ligands to bacteriophage T4 DNA polymerase. Science 1990, 249:505-510.
3. Ellington A.D., Szostak J.W. In vitro selection of RNA molecules that bind specific ligands. Nature 1990, 346:818-822.
4. Hermann T., Patel D.J. Adaptive recognition by nucleic acid aptamers. Science 2000, 287:820-825.
5. Nimjee S.M., Rusconi C.P., Sullenger B.A. Aptamers: an emerging class of therapeutics. Annu Rev Med 2005, 56:555-583.
6. Ng E.W.M., Shima D.T., Calias P., Cunningham E.T., Guyer D.R., Adamis A.P. Pegaptanib, a targeted anti-VEGF aptamer for ocular vascular disease. Nature Rev Drug Dis 2006, 5:123-132.
7. Jayasena S.D. Aptamers: an emerging class of molecules that rival antibodies in diagnostics. Clin Chem 1999, 9:1628-1650.
8. Bruno J.G. A review of therapeutic aptamer conjugates with emphasis on new approaches. Pharmaceuticals 2013, 6:340-357.
9. Reinemann C., Strehlitz B. Aptamer-modified nanoparticles and their use in cancer diagnostics and treatment. Swiss Med Wkly 2014, 144:w13908.
10. Tombelli S., Minunni M., Mascini M. Analytical applications of aptamers. Biosens Bioelectron 2005, 20:2424-2434.
11. Keefe A.D., Pai S., Ellington A. Aptamers as therapeutics. Nature Rev Drug Dis 2010, 9:537-550.
12. Burnett J.C., Rossi J.J. RNA-based therapeutics: current progress and future prospects. Chem Biol 2012, 19:60-71.
13. Sundaram P., Kurniawan H., Byrne M.E., Wower J. Therapeutic RNA aptamers in clinical trials. Eur J Pharm Sci 2013, 48:259-271.
14. Miyakawa S., Nomura Y., Sakamoto T., Yamaguchi Y., Kato K., Yamazaki S., et al. Structural and molecular basis for hyperspecificity of RNA aptamer to human IgG. RNA 2008, 14:1154-1163.
15. Nomura Y., Sugiyama S., Sakamoto T., Miyakawa S., Adachi H., Takano K., et al. Conformational plasticity of RNA for target recognition as revealed by the 2.15Å crystal structure of a human IgG-aptamer complex. Nucleic Acid Res 2010, 38:7822-7829.
16. Nezlin R., GheŤie V. Interactions of immunoglobulins outside the antigen-combining site. Adv Immunol 2004, 82:155-215.
17. Sakai N., Masuda H., Akitomi J., Yagi H., Yoshida Y., Horii K., et al. RNA aptamers specifically interact with the Fc region of mouse IgG. Nucleic Acid Symp Ser (Oxf) 2008, 52:487-488.
18. Ma J., Wang M.G., Mao A.H., Zeng J.Y., Liu Y.Q., Wang X.Q., et al. Target replacement strategy for selection of DNA aptamers against the Fc region of mouse IgG. Genet Mol Res 2013, 12:1399-1410.
19. Yoshida Y., Sakai N., Masuda H., Furuichi M., Nishikawa F., Nishikawa S., et al. Rabbit antibody detection with DNA aptamers. Anal Biochem 2008, 375:217-222.
20. Gokulrangan G., Unruh J.R., Holub D.F., Ingram B., Johnson C.K., Wilson G.S. DNA aptamer-based bioanalysis of IgE by fluorescence anisotropy. Anal Chem 2005, 77:1963-1970.
21. Pastor F., Soldevilla M.M., Villanueva H., Kolonias D., Inoges S., de Cerio A.L., et al. CD28 aptamers as powerful immune response modulators. Mol Ther Nuleic Acids 2013, 2:e98.
22. Santulli-Marotto S., Nair S.K., Rusconi C., Sullinger B., Gilboa E. Multivalent RNA aptamers that inhibit CTLA-4 and enhance tumor immunity. Cancer Res 2003, 63:7483-7489.
23. + T cells and inhibit tumor growth in mice. J Clin Invest 2008, 118:376-386.
24. Gilboa E., McNamara J., Pastor F. Use of oligonucleotide aptamer ligands to modulate the function of immune receptors. Clin Cancer Res 2013, 19:1054-1062.
25. Dollins C.M., Nair S., Boczkowski D., Lee J., Layzer J.M., Gilboa E., et al. Assembling OX40 aptamers on a molecular scaffold to create a receptor-activating aptamer. Chem Biol 2008, 15:675-682.
26. Berezhnoy A., Stewart C.A., McNamara J.O., Thiel W., Giangrande P., Trinchiery G., et al. Isolation and optimization of murine IL-10 receptor blocking oligonucleotide aptamers using high-throughput sequencing. Mol Ther 2012, 20:1242-1250.
27. Berezhnoy A., Castro I., Levay A., Malek T.R., Gilboa E. Aptamer-targeted inhibition of mTOR in T cells enhances antitumor immunity. J Clin Invest 2014, 24:188-197.
28. Pastor F., Kolonias D., McNamara J.O., Gilboa E. Targeting 4-1BB costimulation to disseminated tumor lesions with bi-specific oligonucleotide aptamers. Mol Ther 2011, 19:1878-1886.
29. Pastor F., Kolonias D., Giangrande P., Gilboa E. Induction of tumor immunity by targeted inhibition of nonsense-mediated mRNA decay. Nature 2010, 465:27-31.
30. Gilboa E. Expression of new antigens on tumor cells by inhibiting nonsense-mediated mRNA decay. Immunol Res 2013, 57:44-51.
31. Mallikaratchy P.R., Ruggiero A., Gardner J.R., Kuryavyi V., Maguire W.F., Heaney M.L., et al. A multivalent DNA aptamer specific to the B-cell receptor on human lymphoma and leukemia. Nucleic Acids Res 2011, 39:2458-2469.
32. Krieg A.M. Toll-like receptor 9 (TLR9) agonist in the treatment of cancer. Oncogene 2008, 27:161-167.
33. Krieg A.M. CpG rocks! Update on an accidental drug. Nucleic Acids Ther 2012, 22:77-89.
34. Biesecker G., Dihel L., Enney K., Bendele R.A. Derivation of RNA aptamer inhibitors of human complement C5. Immunopharmacology 1999, 42:219-230.
35. Hoehlig K., Maasch C., Shushakova N., Buchner K., Huber-Lang M., et al. A novel c5a-neutralizing mirror-image (l-) aptamer prevents organ failure and improves survival in experimental sepsis. Mol Ther 2013, 21:2236-2246.
36. Darisipudi M.N., Kulkarni O.P., Sayyed S.G., Ryu M., Migliorini A., Sagrinati C., et al. Dual blockade of the homeostatic chemokine CXCL12 and the proinflammatory chemokine CCL2 has additive protective effects on diabetic kidney. Am J Pathol 2011, 21:116-124.
37. Yoshida Y., Waga I., Horii K. Quantitative and sensitive protein detection strategies based on aptamers. Proteom Clin Appl 2012, 6:574-580.
38. Gold L., Ayers D., Bertino J., Bock C., Bock A., Brody E.N., et al. Aptamer-based multiplexed proteomic technology for biomarker discovery. PloS ONE 2010, 5:e15004.
39. Baldrich E., Restrepo A., O'Sullivan C.K. Aptasensor development: elucidation of critical parameters for optimal aptamer performance. Anal Chem 2004, 76:7053-7063.
40. Luo Y., Liu X., Jiang T., Liao P., Fu W. Dual-aptamer-based biosensing of toxoplasma antibody. Anal Chem 2013, 85:8354-8360.
41. Mahlknecht G., Maron R., Mancini M., Schechter B., Sela M., Yarden Y. Aptamer to ErbB-2/HER2 enhances degradation of the target and inhibits tumorigenic growth. Proc Natl Acad Sci U S A 2013, 110:8170-8175.
42. Kruspe S., Mittelberger F., Szameit K., Hahn U. Aptamers as drug delivery vehicles. ChemMedChem 2014, 9:1998-2011.
43. Zhou J., Rossi J.J. Cell-type-specific, aptamer-functionalized agents for targeted disease therapy. Mol Ther Nucleic Acid 2014, 3:e169.